VistaGen Therapeutics, Inc. (VTGN) Revenue History
Annual and quarterly revenue from 2009 to present
VTGN Revenue Over Time (2009–2026)
VTGN Revenue Growth History
3 of 8 years with positive growth- FY2009 revenue growth
- N/A
- FY2010 revenue growth
- N/A
- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- -85.1%
- FY2014 revenue growth
- -100.0%
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- -100.0%
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- +1.8%
- FY2023 revenue growth
- -120.5%
- FY2024 revenue growth
- +568.7%
- FY2025 revenue growth
- -54.3%
- FY2026 revenue growth
- +161.1%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2026 | $465K | +3200.0% |
| Q3 2026 | $303K | +29.5% |
| Q2 2026 | $258K | +41.0% |
| Q1 2026 | $244K | +190.5% |
| Q4 2025 | $-15,000 | -107.6% |
| Q3 2025 | $234K | -43.1% |
| Q2 2025 | $183K | -34.2% |
| Q1 2025 | $84K | -52.5% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2022)
VTGN's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
VTGN Revenue Analysis (2009–2026)
Current Revenue & Growth
As of June 30, 2026, VistaGen Therapeutics, Inc. (VTGN) generated trailing twelve-month (TTM) revenue of $1.3 million. The most recent quarter (Q4 2026) recorded $465,000 in revenue, up 53.5% sequentially.
Historical Growth Trajectory
VTGN's 5-year compound annual growth rate (CAGR) stands at +3.1%, indicating moderate growth over time. VistaGen Therapeutics, Inc.'s highest annual revenue of $1.3 million was recorded in 2012.
Revenue by Segment
VTGN's revenue is primarily driven by License (100%). With over half of revenue concentrated in License, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ALTO (-3.7% YoY), AXSM (+63.9% YoY), and INVA (+13.6% YoY). Compare VTGN vs ALTO →
VTGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VTGNCurrent | $1M | - | +3.1% | -5683.7% | |
 ALTO | $918M | -3.7% | +0.5% | 0.8% | |
 AXSM | $638M | +63.9% | - | -26.5% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% |
VTGN Historical Revenue Data (2009–2026)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2026 | $1.3M | +161.1% | $1.3M | 100.0% | $-72,126,000 | -5683.7% |
| 2025 | $486K | -54.3% | $486K | 100.0% | $-55,973,000 | -11517.1% |
| 2024 | $1.1M | +568.7% | $1.1M | 100.0% | $-33,021,000 | -3103.5% |
| 2023 | $-227,000 | -120.5% | $-227,000 | 100.0% | $-59,268,000 | 26109.3% |
| 2022 | $1.1M | +1.8% | $1.1M | 100.0% | $-47,778,900 | -4308.7% |
| 2021 | $1.1M | - | $1.1M | 100.0% | $-17,933,800 | -1646.1% |
| 2020 | $0 | - | $-103,100 | - | $-19,974,500 | - |
| 2019 | $0 | - | $0 | - | $-24,556,300 | - |
| 2018 | $0 | -100.0% | $0 | - | $-14,199,600 | - |
| 2017 | $1.3M | - | $1.3M | 100.0% | $-10,248,500 | -819.9% |
| 2016 | $0 | - | $0 | - | $-17,850,200 | - |
| 2015 | $0 | - | $0 | - | $-6,777,100 | - |
| 2014 | $0 | -100.0% | $0 | - | $-5,028,900 | - |
| 2013 | $200K | -85.1% | $200K | 100.0% | $-6,793,100 | -3389.8% |
| 2012 | $1.3M | - | $1.3M | 100.0% | $-9,043,400 | -673.8% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VTGN — Frequently Asked Questions
Quick answers to the most common questions about buying VTGN stock.
Is VTGN's revenue growth accelerating or slowing?
VTGN TTM revenue: $1M. YoY growth: N/A. 5-year CAGR: +3.1%.
What is VTGN's revenue history from 2009 to 2026?
VistaGen Therapeutics, Inc. (VTGN) revenue history spans 2009 to 2026. TTM revenue as of 2026 is $1M, growing at N/A YoY. The 5-year CAGR is +3.1%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is VTGN's long-term revenue growth rate (CAGR)?
VistaGen Therapeutics, Inc.'s 5-year revenue CAGR of +3.1% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for VTGN.
Why does VTGN's quarterly revenue fluctuate?
VTGN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. VistaGen Therapeutics, Inc.'s revenue data from 2009 to 2026 shows full historical quarterly detail on this page.
How is VTGN's revenue distributed by segment?
VTGN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does VTGN's revenue compare to industry peers?
VistaGen Therapeutics, Inc. (VTGN) with TTM revenue of $1M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.